BioSpace News Archive

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced the launch of Biomark™ X, the latest generation of its industry-leading Biomark microfluidics platform.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced it has launched Lucid Test Centers in three new metropolitan areas—Denver, Salt Lake City, and Las Vegas.

Abveris today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets.

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report updated clinical and translational data from its pivotal SPEARHEAD-1 trial with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society (CTOS) annual meeting.

Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer.

A scientist at Hospital for Special Surgery, Chitra Dahia, PhD, has received two National Institutes of Health grants totaling $6 million for translational research aimed at understanding the root cause of disc degeneration and chronic back pain in order to develop treatment options that do not rely on addictive pain-relieving medications.

Immunovia has today published its report for the third quarter 2021.

Gain Therapeutics, Inc., a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, presented preclinical data during a poster session at the Society for Neuroscience Annual Meeting, being held virtually from November 8 – 11, 2021.

Regeneron Pharmaceuticals, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S. and Ronapreve™ in the European Union and other countries.

Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all.